Showing 2481-2490 of 4063 results for "".
- Zenni Optical Announces 2023 Eye Care Access Scholarship Winnershttps://modernod.com/news/zenni-optical-announces-2023-eye-care-access-scholarship-winners/2482062/Zenni Optical has awarded five optometry students with its 2023 Eye Care Access Scholarship. Now in its second year, the Zenni Eye Care Access Scholarship recognizes incoming students who want to provide eye care to communities in need everywhere.
- IntRIS Hosts ARCR Macular 2024 Meeting and Presents Interview With FDA’s Dr. Wiley Chambershttps://modernod.com/news/intris-hosts-arcr-macular-2024-meeting-and-presents-interview-with-fdas-dr-wiley-chambers/2482057/The International Retinal Imaging Society (IntRIS) hosted the Atlantic Coast Retina Club (ACRC) Macula 2024, led by K. Bailey Freund, MD. According IntRIS, the ACRC meeting format includes rapid-fire single-case presentations, engaging discussions, and conferences covering diverse retin
- iSTAR Medical Continues European Expansion with First MINIject Surgeries in the Netherlandshttps://modernod.com/news/istar-medical-continues-european-expansion-with-first-miniject-surgeries-in-the-netherlands/2482027/iSTAR Medical announced the successful first implantations of MINIject, the company’s bio-integrating, minimally-invasive glaucoma surgery (MIGS) device, in the Netherlands. Patients were successfully implanted at the University Eye Clinic of the Maastricht University Medical Center+ b
- Clearside Biomedical Completes Randomization in Phase 2b Clinical Trial of CLS-AX in Wet AMDhttps://modernod.com/news/clearside-biomedical-completes-randomization-in-phase-2b-clinical-trial-of-cls-ax-in-wet-amd/2482013/Clearside Biomedical announced it has completed randomization in its ODYSSEY Phase 2b clinical trial of CLS-AX (axitinib injectable suspension) in wet age-related macular degeneration (AMD). Topline data results are expected in the third quarter of 2024. “As we continue
- Prevent Blindness President & CEO Jeff Todd to Lead 2024 National Health Council Board of Directorshttps://modernod.com/news/prevent-blindness-president-ceo-jeff-todd-to-lead-2024-national-health-council-board-of-directors/2482007/At the National Health Council (NHC) annual membership meeting, Jeff Todd, President & Chief Executive Officer of Prevent Blindness, was named the Chair of the NHC Board of Directors for 2024. “Jeff Todd is an excellent choice to lead our Board in 2024,” said R
- Tarsus Announces Topline Phase 2a Trial Results Evaluating TP-03 for the Treatment of MGD in Patients with Demodex Miteshttps://modernod.com/news/tarsus-announces-topline-phase-2a-trial-results-evaluating-tp-03-for-the-treatment-of-mgd-in-patients-with-demodex-mites/2482004/Tarsus Pharmaceuticals announced topline results from the Ersa phase 2a clinical trial evaluating TP-03 (lotilaner ophthalmic solution, 0.25%) administered twice daily (BID) or three times a day (TID) for 12 weeks for the treatment of meibomian gland disease (MGD) in patients with Demodex&nb
- Oculis Begins Phase 2b RELIEF Trial of Topical Anti-TNFα Licaminlimab (OCS-02) in Dry Eye Diseasehttps://modernod.com/news/oculis-begins-phase-2b-relief-trial-of-topical-anti-tnfa-licaminlimab-ocs-02-in-dry-eye-disease/2481998/Oculis announced 'First Patient First Visit' (FPFV) in its phase 2b RELIEF trial evaluating the potential of licaminlimab (also known as OCS-02), Oculis’ anti-TNFα biologic eye drop drug candidate for the treatment of dry eye disease (DED). The phase 2b REL
- KeraLink International Provides $2.5 Million in Seed Funding to Enable Development of Bioengineered Corneal Implantshttps://modernod.com/news/keralink-international-provides-25-million-in-seed-funding-to-enable-development-of-bioengineered-corneal-implants/2481970/KeraLink International (KLI) announced $2.5 million in seed funding in Pantheon Vision (PV) to launch the development of a novel advancement to help eradicate corneal blindness in both developed and low- and middle-income countries (LMICs). Pantheon Vision, an early-stage ophthalmic med
- Visionix Announces Strategic Partnership with 20/20NOWhttps://modernod.com/news/visionix-announces-strategic-partnership-with-2020now/2481957/Visionix USA announced it has entered a into a strategic alliance with 20/20NOW with the aim of bringing cost-effective, in-office, synchronous tele-optometry eye exams and ocular telemedicine closer to more patients throughout the United States. Financial terms of the deal we
- Pantheon Vision Raises $2.5 Million in Seed Funding to Launch Development of Bioengineered Corneal Implanthttps://modernod.com/news/pantheon-vision-raises-25-million-in-seed-funding-to-launch-development-of-bioengineered-corneal-implant/2481936/Pantheon Vision has announced $2.5 million in seed financing from Baltimore-based KeraLink International (KLI), a non-profit organization singularly focused on eradicating corneal blindness with an emphasis on low- and middle-income countries. The funding will be us